Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1101-1110 of 1,835) with videos related to

Pageof 184
Sort By:
Mabs|December 6, 2018
Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeuticsStefan Harth, Andre Ten Haaf, Christian Loew, et al.
Mabs|December 8, 2018
In vitro and in silico assessment of the developability of a designed monoclonal antibody libraryAdriana-Michelle Wolf Pérez, Pietro Sormanni, Jonathan Sonne Andersen, et al.
Mabs|December 15, 2018
Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo propertiesAyse Meric Ovacik, Ji Li, Marie Lemper, et al.
Mabs|March 20, 2018
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumabNeungseon Seo, Alla Polozova, Mingxuan Zhang, et al.
Mabs|June 22, 2022
Antigenic landscapes on <i>Staphylococcus aureus</i> pore-forming toxins reveal insights into specificity and cross-neutralizationShweta Kailasan, Ravi Kant, Madeleine Noonan-Shueh, et al.
Mabs|July 8, 2022
Mechanistic insights into the rational design of masked antibodiesCarolina T Orozco, Manuela Bersellini, Lorraine M Irving, et al.
Mabs|June 2, 2021
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab <i>in vitro</i>Haolin Liu, Pengcheng Wei, Qianqian Zhang, et al.
Mabs|February 15, 2020
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapyRita De Santis
Mabs|February 18, 2020
10<sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsS Tourdot, A Abdolzade-Bavil, J Bessa, et al.
Mabs|January 31, 2020
Improved translation of stability for conjugated antibodies using an in vitro whole blood assayAimee Fourie-O'Donohue, Phillip Y Chu, Josefa Dela Cruz Chuh, et al.
Pageof 184

Showing results (1101-1110 of 1,835) with videos related to

Sort By:
Pageof 184
Mabs|December 6, 2018
Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeuticsStefan Harth, Andre Ten Haaf, Christian Loew, et al.
Mabs|December 8, 2018
In vitro and in silico assessment of the developability of a designed monoclonal antibody libraryAdriana-Michelle Wolf Pérez, Pietro Sormanni, Jonathan Sonne Andersen, et al.
Mabs|December 15, 2018
Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo propertiesAyse Meric Ovacik, Ji Li, Marie Lemper, et al.
Mabs|March 20, 2018
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumabNeungseon Seo, Alla Polozova, Mingxuan Zhang, et al.
Mabs|June 22, 2022
Antigenic landscapes on <i>Staphylococcus aureus</i> pore-forming toxins reveal insights into specificity and cross-neutralizationShweta Kailasan, Ravi Kant, Madeleine Noonan-Shueh, et al.
Mabs|July 8, 2022
Mechanistic insights into the rational design of masked antibodiesCarolina T Orozco, Manuela Bersellini, Lorraine M Irving, et al.
Mabs|June 2, 2021
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab <i>in vitro</i>Haolin Liu, Pengcheng Wei, Qianqian Zhang, et al.
Mabs|February 15, 2020
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapyRita De Santis
Mabs|February 18, 2020
10<sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticalsS Tourdot, A Abdolzade-Bavil, J Bessa, et al.
Mabs|January 31, 2020
Improved translation of stability for conjugated antibodies using an in vitro whole blood assayAimee Fourie-O'Donohue, Phillip Y Chu, Josefa Dela Cruz Chuh, et al.
Pageof 184